Moderna (MRNA) Revenue — Quarter Ended Dec 31, 2023
Revenue for the quarter increased sharply from the prior quarter. Compared to the same quarter a year earlier, revenue declined substantially.
Key takeaway
Quarter ended Dec 31, 2023 · FY2023 Q4
Revenue for the quarter increased sharply from the prior quarter. Compared to the same quarter a year earlier, revenue declined substantially.
Financial snapshot
Reported revenue, sequential change, year-over-year change, and trailing four-quarter revenue.
Quarter revenue
$2.8B
Revenue reported for this quarter.
Quarter-over-quarter
+53.5%
Change from the immediately preceding quarter.
Year-over-year
-44.7%
Change from the comparable year-ago quarter.
Trailing four quarters
$6.8B
Sum of the latest four reported quarters.
Quarterly revenue trend
The latest four reported quarters with year-over-year comparisons.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Mar 31, 2023 | $1.9B | -69.3% |
| Jun 30, 2023 | $344M | -92.8% |
| Sep 30, 2023 | $1.8B | -45.6% |
| Dec 31, 2023 | $2.8B | -44.7% |
Revenue performance
The reported revenue rose sequentially, reversing the prior quarter's decline. The year-over-year comparison shows a significant drop from the same period last year.
Quarterly comparison
Revenue was higher than the immediately preceding quarter but lower than the same quarter one year earlier. The sequential improvement contrasts with the annual decline.
What to watch
The filing context notes a decrease in cash, cash equivalents, and investments compared to the prior year, primarily due to operating activities and stock repurchases.